1. Home
  2. FOLD

FOLD

Amicus Therapeutics Inc.

Logo Amicus Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Founded: 2002 Country:
United States
United States
Employees: N/A City: PHILADELPHIA
Market Cap: 3.2B IPO Year: 2007
Target Price: $19.00 AVG Volume (30 days): 3.0M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.51 EPS Growth: N/A
52 Week Low/High: $9.70 - $14.57 Next Earning Date: 05-08-2024
Revenue: $399,356,000 Revenue Growth: 21.30%
Revenue Growth (this year): 35.67% Revenue Growth (next year): 28.40%

Share on Social Networks: